Business
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today announced t
About this update from Acrivon Therapeutics, Inc.
[{"type":"image","alt":"Acrivon Therapeutics, Inc","displaySize":"","headline":null,"caption":"Acrivon Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/18842H0LzLmEExp9Uy8VVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6","width":300,"height":160}},"lazy":false},{"type":"text","content":"WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of October 1, 2025.","length":695,"tagName":"p"},{"type":"text","content":"The employee received an aggregate of options to purchase 225,000 shares of Acrivon common stock. The stock options have an exercise price per share equal to the closing price of Acrivon’s common stock on the Nasdaq Global Market on the date of grant. The stock options will vest 25% on the first anniversary of the first day of the month following the effective date of such employee’s employment and in additional 2.083% installments on a monthly basis thereafter, subject to such employee’s continued employment on each vesting date.","length":536,"tagName":"p"},{"type":"text","content":"The inducement grants were approved by Acrivon’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).","length":206,"tagName":"p"},{"type":"text","content":"About Acrivon Therapeutics ","length":26,"tagName":"p"},{"type":"text","content":"Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Pho...